2024/2025 FLU SEASON

SIMPLIFLU

Making the transition to trivalent influenza vaccines simple

FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older.

Two Vaccines, Same Indication

Fluarix Influenza Vaccine

Carton NDC Code: 58160-884-52

PFS NDC Code: 58160-884-41

CPT Code: 90656

ICD-10 Code: Z23

FluLaval Influenza Vaccine



Carton NDC Code: 19515-810-52

PFS NDC Code: 19515-810-41

CPT Code: 90656

ICD-10 Code: Z23

Presentation: Supplied in 0.5-mL, single-dose, prefilled, *Tip-Lok* syringes

Tip caps and plungers of the prefilled syringes are not made with natural rubber latex

Does not contain thimerosal

Case dimensions: 13" x 9.06" x 8" **Unit dimensions:** 3.9" x 6.97" x 0.79"

2D barcodes on product and packaging

Questions?

- Call 1-855-475-4748 or visit us at **GSKDirect.com**
- Contact your GSK Vaccines sales representative to place an order

Eligible customers who prebook on GSKDirect by **3/31/2024** will receive a **2%** early reservation discount on their **2024-2025** direct prebooked purchases.

Important Safety Information for FLUARIX and FLULAVAL

- Do not administer FLUARIX or FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine

Please see full Important Safety Information for FLUARIX and FLULAVAL on reverse.

Please see accompanying full Prescribing Information for FLUARIX and for FLULAVAL, or visit GSK Products at gskpro.com.

Indication for FLUARIX and FLULAVAL

FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX and FLULAVAL

- Do not administer FLUARIX or FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX or FLULAVAL should be based on careful consideration of the potential benefits and risks
- Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX and FLULAVAL. Procedures should be in place to avoid injury from fainting
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUARIX and FLULAVAL
- If FLUARIX or FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
- The most common (≥10%) solicited local adverse reactions with FLUARIX in adults were pain (55%) and redness (18%), and the most common systemic adverse reactions were muscle aches (23%), fatigue (20%), and headache (19%). In children aged 5 through 17 years, the most common (≥10%) solicited local adverse reactions were pain (56%), redness (18%), and swelling (14%), and the most common systemic adverse reactions were muscle aches (29%), fatigue (20%), and headache (15%). In children aged 3 through 4 years, the most common (≥10%) solicited local adverse reactions were pain (35%), redness (23%), and swelling (14%), and the most common systemic adverse reactions were irritability (21%), loss of appetite (13%), and drowsiness (13%). In children aged 6 through 35 months who received FLUARIX QUADRIVALENT, the most common (≥10%) solicited local adverse reactions were pain (17%) and redness (13%), and the most common systemic adverse reactions were irritability (16%), loss of appetite (14%), and drowsiness (13%)
- The most common (≥10%) solicited local adverse reactions with FLULAVAL in adults were pain (51%), redness (13%), and swelling (11%), and the most common solicited systemic adverse reactions were fatigue (20%), headache (18%), and muscle aches/arthralgia (18%). In children aged 3 through 17 years, the most common (≥10%) solicited local adverse reaction was pain (56%). In children aged 3 through 4 years, the most common (≥10%) solicited systemic adverse reactions were irritability (25%), drowsiness (19%), and loss of appetite (16%). In children aged 5 through 17 years, the most common (≥10%) solicited systemic adverse reactions were muscle aches (24%), headache (17%), and fatigue (17%). In children aged 6 through 35 months who received FLULAVAL QUADRIVALENT, the most common (≥10%) solicited local adverse reaction was pain (40%), and the most common solicited systemic adverse reactions were irritability (49%), drowsiness (37%), and loss of appetite (29%)
- Vaccination with FLUARIX or FLULAVAL may not result in protection of all vaccine recipients

Please see accompanying full Prescribing Information for FLUARIX and for FLULAVAL, or visit GSK Products at gskpro.com.

Return Privileges: Based on your purchasing agreement, a % of your seasonal GSK flu vaccine doses purchased via GSKDirect may be eligible to be returned for full credit (the % return eligibility is applied in the aggregate across brands). In order to qualify for return reimbursement of eligible flu vaccine doses, customers must obtain a GSK-issued Return Goods Authorization (RGA).*† The RGA can be obtained via GSKDirect.com or by calling the GSK Vaccine Service Center at 1-866-475-8222.

Eligible flu vaccine doses returned must be received at the GSK Return Goods Vendor (PharmaLink) within the Flu Vaccine Return Period. GSK will notify eligible customers of the return window begin date and end date ("The Flu Vaccine Return Period") and when the RGA will be available. Flu vaccines returned without the RGA and/or received outside of the eligible Flu Vaccine Return Period will be reimbursed Federal Excise Tax (FET) only.*†

Ground shipping can take in excess of 7 days. Please plan accordingly to ensure your vaccines are returned before the end of the return window. The labels are only applicable for the current season's flu products. Do not return any other vaccine products with this label.

With the exception of terms that conflict with the purchasing agreement (in which case the purchasing agreement terms supersede all other provisions), all other GSK Return Goods Policy provisions apply as published on GSKDirect.com. The GSK Return Goods Policy is subject to change on GSKDirect.com without notice.

*The initial number of eligible doses to return will not decrease as doses are returned. Please contact the Vaccine Service Center for an update to the number of doses eligible to return.

†GSK-issued Return Goods Authorization (RGA) — GSK will provide customers with a document in the form of a debit memo authorizing the return of eligible flu vaccine doses. Please note, the creation of a return box label through the GSK Return Goods Vendor (PharmaLink) is not a guarantee of reimbursement and is not to be used in place of a GSK-issued RGA.

Fluarix Influenza Vaccine

FluLaval Influenza Vaccine

GSK

PMUS-FLULBND240010 September 2024
Produced in USA. 0002-0033-10